Target intelligence / Profile preview

Gut microbiota community and intestinal barrier

Molecular classification
Other
01

Overview

The gut microbiota community and intestinal barrier constitute a critical physiological interface responsible for maintaining systemic homeostasis and protecting the host from environmental insults (Thursby & Juge, 2017, Biochemical Journal). The intestinal barrier is a multi-layered structure composed of a mucus layer, a single layer of epithelial cells connected by tight junctions, and an underlying immune system, while the microbiota consists of a diverse ecosystem of bacteria, fungi, and viruses (Vancamelbeke & Vermeire, 2017, Therapeutic Advances in Gastroenterology). Together, they regulate nutrient absorption, synthesize essential metabolites like short-chain fatty acids, and educate the mucosal immune system to distinguish between commensal organisms and pathogens (Bischoff et al., 2014, BMC Gastroenterology). Disruptions in this delicate balance, often referred to as leaky gut or dysbiosis, are linked to the pathogenesis of various conditions, including inflammatory bowel disease, metabolic disorders, and autoimmune diseases (Fasano, 2011, Physiological Reviews). Therapeutic interventions focus on restoring microbial diversity and reinforcing barrier integrity through pharmacological agents like Rifaximin, dietary modifications, and microbial transfers (Ponziani et al., 2017, World Journal of Gastroenterology).

Other names
Intestinal mucosal barrierGut-microbiota axisGut-intestinal interfaceIntestinal permeability system
02

Mechanism of action

Modulation of microbial diversity, enhancement of tight junction protein expression (e.g., zonulin, occludin), and production of anti-inflammatory metabolites like short-chain fatty acids (SCFAs) (Bischoff et al., 2014, BMC Gastroenterology).

03

Biological functions

Immune responseMetabolismBarrier integrityPathogen defenseHomeostasis
04

Disease associations

Inflammatory bowel diseaseIrritable bowel syndromeObesityType 2 diabetesNonalcoholic fatty liver diseaseCeliac diseaseSepsis
05

Safety considerations

Risk of systemic infectionInduction of dysbiosisUnpredictable metabolic shiftsTransfer of antibiotic resistance genes
06

Interacting drugs

Rifaximin

5 more in the full profile.

07

Biomarkers

ZonulinFecal calprotectinShort-chain fatty acidsLipopolysaccharide (LPS)16S rRNA microbial profiling

Beyond the preview

Go deeper on Gut microbiota community and intestinal barrier.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gut microbiota community and intestinal barrier.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call